Sun Pharma, AstraZeneca Sign Distribution Pact for Diabetes Drug in India
By

Sun Pharma and AstraZeneca Pharma India Limited have formed a partnership for the distribution of dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is AstraZeneca India's leading diabetes medicine.

Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name Oxra. AstraZeneca India markets dapagliflozin under the brand name Forxiga and under the terms of the agreement, both companies will promote, market, and distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.

Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name Oxramet, following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin.

Source: Sun Pharma

Leave a Reply

Your email address will not be published.